Skip to main content

Table 2 Characteristics of the sample by depression screening, documentation and prescription of antidepressant medication

From: Do competing demands of physical illness in type 2 diabetes influence depression screening, documentation and management in primary care: a cross-sectional analytic study in Aboriginal and Torres Strait Islander primary health care settings

Variables Total sample Screened with standard named tool Documented depression Prescription of antidepressant medication
  n % n % OR 95% CI n % OR 95% CI n % OR* 95% CI
Total 1174 100 57 5.0     70 6.0     65 5.5    
Sex                  
Male 489 41.7 22 4.5 Reference   25 5.1 Reference   25 5.1 Reference  
Female 685 58.3 35 5.1 1.14 0.69 1.89 45 6.6 1.31 0.73 2.34 40 5.8 1.15 0.57 2.32
Age group                  
15-35 years 111 9.5 2 1.8 Reference   4 3.6 Reference   4 3.6 Reference  
35-49 years 434 37.0 20 4.6 2.63* 1.51 4.60 35 8.1 2.35 0.84 6.58 24 5.5 1.57 0.56 4.37
50-64 years 450 38.3 16 3.6 2.01 0.69 5.89 24 5.3 1.51 0.51 4.49 28 6.2 1.77 0.62 5.08
65+ years 179 15.2 19 10.6 6.47 1.26 33.27 7 3.9 1.09 0.35 3.40 9 5 1.42 0.45 4.44
Smoking status                  
Non-smoker 769 65.5 32 4.2 Reference   40 5.2 Reference   39 5.1 Reference  
Current smoker 405 34.5 25 6.2 1.52 0.62 3.72 30 7.4 1.48 0.89 2.46 26 6.4 1.28 0.83 1.99
BMI                  
BMI 24 or less 572 50.9 5 0.9 Reference   19 3.3 Reference   23 4 Reference  
BMI>24 551 49.1 52 9.4 11.82** 3.58 39.02 47 8.5 2.71* 1.35 5.46 39 7.1 1.82 0.87 3.80
Ischaemic heart disease                 
No 951 81.0 41 4.3 Reference   55 5.8 Reference   49 5.2 Reference  
Yes 223 19.0 16 7.2 1.72 0.71 4.14 15 6.7 1.17 0.7 2.10 16 7.2 1.42 0.72 2.82
Renal disease                  
No 742 63.2 48 6.5 Reference   58 7.8 Reference   47 6.3 Reference  
Yes 432 36.8 9 2.1 0.31** 0.17 0.56 12 2.8 0.34** 0.2 0.75 18 4.2 0.64 0.33 1.26
ACR level                  
<=3.4 270 33.8 28 10.4 Reference   17 6.3 Reference   17 6.3 Reference
>3.4 528 66.2 11 2.8 0.18** 0.09 0.37 29 5.5 0.87 0.4 1.8 22 4.2 0.65 0.3 1.23
Hypertension                  
No 491 41.8 19 3.9 Reference   24 4.9 Reference   20 4.1 Reference  
Yes 683 58.2 38 5.6 1.46 0.75 2.87 46 6.7 1.41 0.8 2.34 45 6.6 1.66 0.96 2.88
Hyperlipidaemia†                  
No 629 53.6 19 3.0 Reference   29 4.6 Reference   96 26 Reference  
Yes 545 46.4 38 7.0 2.41* 1.30 4.46 41 7.5 1.68* 1.1 2.66 39 7.2 1.79* 1.07 2.97
Diabetes treatment                 
No medication 150 14.3 14 8.3 Reference   11 6.5 Reference   11 6.5 Reference  
Oral 678 63.8 29 3.9 0.44* 0.26 0.76 40 5.3 0.81 0.40 1.62 40 5.3 0.80 0.42 1.50
Insulin 222 21.9 14 5.4 0.63 0.38 1.04 19 7.4 1.14 0.50 2.58 19 7.4 1.26 0.53 3.01
HbA1c level                  
<=7.00% 301 30.0 28 9.3 Reference   27 9 Reference   19 6.3 Reference  
>7.00%* 702 70.0 25 3.6 0.36** 0.23 0.55 36 5.1 0.55* 0.34 0.88 35 5 0.78 0.46 1.31
Total cholesterol                  
<=4.00 mmol1-1 323 34.9 21 6.5 Reference   20 6.2 Reference   10 3.1 Reference  
>4.00 mmol 1-1 603 65.1 30 5 0.75 0.46 1.24 40 6.6 1.08 0.72 1.61 39 6.5 2.16 0.99 4.73
Blood pressure                  
<=130/80 mmHg 404 36.4 19 4.7 Reference   25 6.2 Reference   22 5.4 Reference  
>130/80 mmHg 706 63.6 37 5.2 1.12 0.63 1.98 41 5.8 0.93 0.66 1.33 37 5.2 0.96 0.54 1.70
*P<0.01; **P<0.001                 
  1. Significance tests adjusted for clustering by health centre. Sample size might vary with missing data. BMI, body mass index.
  2. † Further analysis (not shown in the table) revealed that the association between hyperlipidaemia and depression & screening was mediated by BMI; after adjusting for this interaction, no substantial effect of hyperlipidaemia on depression indicators remained.